Kaivosaari Sanna, Toivonen Päivi, Aitio Olli, Sipilä Julius, Koskinen Mikko, Salonen Jarmo S, Finel Moshe
Centre for Drug Research, Faculty of Pharmacy, University of Helsinki, P.O. Box 56 (Viikinkaari 5), 00014 University of Helsinki, Finland.
Drug Metab Dispos. 2008 Aug;36(8):1529-37. doi: 10.1124/dmd.108.021709. Epub 2008 May 12.
Medetomidine is a chiral imidazole derivate whose dextroenantiomer is pharmacologically active. The major metabolic pathway of dexmedetomidine [(+)-4-(S)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole] in humans is N-glucuronidation at the imidazolate nitrogens. We have purified the N3- and N1-glucuronides of dexmedetomidine, termed DG1 and DG2, respectively, according to their elution order in liquid chromatography and determined their structure by 1H nuclear magnetic resonance (NMR). Studying medetomidine glucuronidation by human liver microsomes (HLMs) and recombinant UDP glucuronosyltransferase (UGT) 1A4 indicated that another human UGT plays a major role in these activities. We now demonstrate that this enzyme is UGT2B10. HLMs catalyzed DG1 and DG2 formation, at a ratio of 3:1, with two-enzyme kinetics that contain both a high-affinity component, K(m1) values of 6.6 and 8.7 microM, and a low-affinity component, K(m2) values > 1 mM. The DG1/DG2 ratio in the case of UGT2B10 was lower, 1.4:1, whereas the substrate affinity for both reactions was high, K(m) values of 11 and 16 microM. UGT1A4 produced mainly DG1 (DG1/DG2 ratio of 6.6:1) at low substrate affinities, K(m) values above 0.6 mM, but superior expression-normalized V(max) values. Levomedetomidine [(-)-4-(R)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole] glucuronidation by HLMs yielded mostly the N3-glucuronide (LG1, structure determined by NMR), with monophasic kinetics and a K(m) value of 14 microM. The activity of UGT1A4 toward levomedetomide was low and generated both LG1 and LG2, whereas UGT2B10 exhibited relatively high activity and sharp regioselectivity, yielding only LG1, with a K(m) value of 7.4 microM. The results highlight the contribution of UGT2B10 to medetomidine glucuronidation and its potential importance for other N-glucuronidation reactions within the human liver.
美托咪定是一种手性咪唑衍生物,其右旋对映体具有药理活性。右美托咪定[(+)-4-(S)-[1-(2,3-二甲基苯基)乙基]-1H-咪唑]在人体内的主要代谢途径是咪唑氮上的N-葡萄糖醛酸化。我们根据右美托咪定的N3-和N1-葡萄糖醛酸苷(分别称为DG1和DG2)在液相色谱中的洗脱顺序对其进行了纯化,并通过1H核磁共振(NMR)确定了它们的结构。用人肝微粒体(HLMs)和重组UDP葡萄糖醛酸基转移酶(UGT)1A4研究美托咪定葡萄糖醛酸化表明,另一种人UGT在这些活性中起主要作用。我们现在证明这种酶是UGT2B10。HLMs以3:1的比例催化DG1和DG2的形成,具有双酶动力学,包含一个高亲和力组分,K(m1)值分别为6.6和8.7 microM,以及一个低亲和力组分,K(m2)值>1 mM。UGT2B10情况下的DG1/DG2比例较低,为1.4:1,而两个反应的底物亲和力都很高,K(m)值分别为11和16 microM。UGT1A4在低底物亲和力(K(m)值高于0.6 mM)下主要产生DG1(DG1/DG2比例为6.6:1),但表达标准化的V(max)值较高。HLMs对左美托咪定[(-)-4-(R)-[1-(2,3-二甲基苯基)乙基]-1H-咪唑]进行葡萄糖醛酸化主要产生N3-葡萄糖醛酸苷(LG1,结构由NMR确定),具有单相动力学,K(m)值为14 microM。UGT1A4对左美托咪定的活性较低,产生LG1和LG2,而UGT2B10表现出相对较高的活性和明显的区域选择性,仅产生LG1,K(m)值为7.4 microM。这些结果突出了UGT2B10对美托咪定葡萄糖醛酸化的贡献及其在人肝脏内其他N-葡萄糖醛酸化反应中的潜在重要性。